Madrigal Pharmaceuticals, Inc. MDGL
Analyst Consensus
Price Objectif
Analyst historical
| Analyst | Entreprise | Price during analysis | Target price | Potential gain | Publication date |
|---|---|---|---|---|---|
| Jay Olson | Oppenheimer | 428.3 $ | 590 $ | 161.70 % | 10/10/2025 |
| Edward Nash | Canaccord Genuity | 315.48 $ | 420 $ | 104.52 % | 02/05/2025 |
| Yasmeen Rahimi | Piper Sandler | 221.755 $ | 336 $ | 114.25 % | 29/05/2024 |
| Ed Acre | H.C. Wainwright | 208.04 $ | 390 $ | 181.96 % | 09/05/2024 |
| Liisa Bayko | Evercore ISI | 265.68 $ | 405 $ | 139.32 % | 19/03/2024 |
| Eliana Merle | UBS | 270.37 $ | 410 $ | 139.63 % | 15/03/2024 |
| Akash Tewari | Jefferies | 270.37 $ | 400 $ | 129.63 % | 15/03/2024 |
| Ed Acre | H.C. Wainwright | 270.37 $ | 425 $ | 154.63 % | 15/03/2024 |
| Jonathan Wolleben | JMP Securities | 270.37 $ | 397 $ | 126.63 % | 15/03/2024 |
| Mayank Mamtani | B.Riley Financial | 270.37 $ | 270 $ | -0.37 % | 15/03/2024 |
| Matthew Luchini | BMO Capital | 90.95 $ | 111 $ | 20.05 % | 06/08/2021 |
| Andrea Tan | Goldman Sachs | 129.77 $ | 195 $ | 65.23 % | 20/05/2021 |
| Derek Archila | Wells Fargo | 126.71 $ | 130 $ | 3.29 % | 06/05/2021 |